Medication Guide App

Fourth Update on Daiichi Sankyo Operations Following the Great East Japan Earthquake

TOKYO, April 21, 2011 – Daiichi Sankyo Company, Limited again offers its deepest sympathy to all those affected by the devastating March 11 Great East Japan Earthquake. The following is an update on the disaster recovery plan of the Daiichi Sankyo Group.

1. Production Situation
(1) Onahama Plant (Iwaki-shi, Fukushima Prefecture) Active pharmaceutical ingredients, including pravastatin and olmesartan, are produced at this plant and work on the restoration of facilities and equipment used in the manufacture of these products is already underway, with September of this year as a goal for the start of production.

(2) Hiratsuka Plant (Hiratsuka-shi, Kanagawa Prefecture) A gradual return to production operations has already been underway, and as of the end of this week, normal operations will have been restored.

2. Effect on Corporate Earnings
Based on information available at this time, the calculated effect on the financial period ending in March 2011 is expected to be 5.5 billion yen. This will be processed as an “extraordinary loss.”

Company name: DAIICHI SANKYO COMPANY, LIMITED
Representative: Joji Nakayama, President and Representative Director
(Code no.: 4568, First Section, Tokyo, Osaka and Nagoya Stock Exchanges)
Please address inquiries to Toshiaki Sai, Corporate Officer,
Vice President, Corporate Communications Department
Telephone: +81-3-6225-1126
http://www.daiichisankyo.com/

 

Posted: April 2011


View comments

Hide
(web2)